drugset
drugset / Trial / NCT06648824

Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants

NCT06648824 ↗

Phase 1 Completed 20 enrolled Agios Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the effect of mitapivat on the single oral dose pharmacokinetics (PK) of midazolam in healthy participants.

Timeline

Start
2024-10-17
Primary completion
2024-12-03
Completion
2024-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg Oral
Subject Mitapivat Small molecule 100 mg Oral

Indications

No indication recorded.